Form 4: Amgen SVP Rachna Khosla Reports Acquisition of Common Stock

Amgen's SVP of Business Development, Rachna Khosla, reports acquiring 1,403 shares of common stock on March 3, 2025.

Summary

• On March 3, 2025, Rachna Khosla, SVP of Business Development at Amgen, acquired 1,403 shares of Amgen common stock.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Ms. Khosla directly owns 9,802 shares of Amgen common stock.
• The reported shares include 145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard SEC filing reporting an insider transaction. The acquisition of shares by an executive could be seen as a mildly positive signal, but without more context, it's difficult to assess the overall impact.

Positives

• The acquisition of shares by a high-ranking officer could be interpreted as a positive signal about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive sign of management's confidence in the company.

Key Dates